Prevention

Do Statins Prevent Events in Adults Over 75 Without Heart Disease?

Quick answer

Statins reduce major vascular events proportionally to LDL lowering across age groups, including over 75, per the CTT meta-analysis. Absolute benefit depends on baseline risk and life expectancy; a moderate-intensity statin is reasonable for a non-frail patient aged 75–85 with estimated 10-year ASCVD risk ≥10% and life expectancy ≥5 years. Avoid in frailty, limited prognosis, or drug-interaction-heavy polypharmacy.

Evidence review

Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.

CTT Collaboration age meta-analysis (2019)

PMID 30712900

186,854 participants across 28 RCTs, subgroup >75

Each 1 mmol/L LDL reduction cut major vascular events 21% overall; in those >75 without prior vascular disease, relative risk reduction was consistent (RR 0.92 per 1 mmol/L, 95% CI 0.84–1.00).

PROSPER (2002)

PMID 12457784

5,804 adults 70–82 with CVD or risk factors

Pravastatin reduced primary endpoint (CHD death/MI/stroke) 15% (HR 0.85, 95% CI 0.74–0.97). Driven by secondary prevention subgroup.

Practical decision algorithm

IfThen
Age 75–85, non-frail, 10-year ASCVD ≥10%, life expectancy ≥5 yrStart moderate-intensity statin (atorvastatin 20 mg or rosuvastatin 5–10 mg).
Age 75–85, ASCVD risk <7.5% or diffuse atherosclerosis absent on imagingShared decision — benefit marginal. CAC or carotid imaging can refine.
Age ≥85 or frail (Clinical Frailty Scale ≥5)Avoid initiating for primary prevention. Consider deprescribing if already on one without clear indication.
Severe polypharmacy with CYP3A4 interactionsPrefer pravastatin or rosuvastatin to minimize interactions.

Guideline position

2018 ACC/AHA cholesterol guideline: reasonable to initiate moderate-intensity statin in adults 75–80 with elevated ASCVD risk (Class 2b). USPSTF 2022: insufficient evidence (I statement) for primary prevention ≥76. 2024 ESC prevention guideline: consider statins in healthy ≥70 with high risk (Class 2b).

Contraindications and cautions

  • Active liver disease with transaminases >3× ULN
  • Pregnancy
  • Prior statin-associated muscle symptoms with confirmed rechallenge intolerance
  • Life expectancy <3 years or severe frailty
  • Anticipated major drug-drug interactions (e.g., cyclosporine + simvastatin)

Frequently asked questions

Does coronary artery calcium help decide?
Yes. A CAC of 0 in a low-intermediate-risk elderly patient supports deferring; CAC ≥100 or ≥75th percentile supports initiating. MESA-derived calculators stratify 10-year risk more precisely than pooled cohort equations in this age group.
What about muscle symptoms in older adults?
Up to 10–15% report muscle symptoms, but RCT-confirmed true statin myalgia is much lower (2–3%). Try a low dose of a hydrophilic statin (pravastatin, rosuvastatin) and monitor CK only if symptomatic.
Should I use a lipophilic or hydrophilic statin?
Hydrophilic agents (pravastatin, rosuvastatin) have fewer CNS and CYP3A4 interactions — often preferable in older adults. No clear efficacy difference at equivalent LDL reduction.
What LDL target should I aim for?
For primary prevention in ≥75, a pragmatic target is LDL reduction ≥30% from baseline, rather than an absolute level. Adding ezetimibe is reasonable if target not met.
When should I deprescribe a statin?
When life expectancy drops below 1–2 years, when new severe frailty develops, when adverse effects dominate, or when the patient enters hospice. A 2024 JAMA Internal Medicine trial supported deprescribing in advanced illness without increased mortality.

Further reading

Clinical Reasoning

Polypharmacy in Elderly Patients: An Evidence-Based Deprescribing Framework

Evidence-Based Medicine

Hypertension Management: 2026 ACC/AHA Blood Pressure Targets and Treatment Updates

Methodology

Shared Decision-Making with Complex Evidence: A Practical Guide

Back to all decision points